What is Beam Therapeutics Inc (BEAM) stock price today?

Beam Therapeutics Inc (BEAM) currently trades at $29.38 per share. The stock has a market capitalization of $3.02B and a P/E ratio of —x.

Is BEAM stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Beam Therapeutics Inc has a Smart Value Score of 35/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Beam Therapeutics Inc's revenue and earnings?

Beam Therapeutics Inc has trailing twelve-month (TTM) revenue of $139.74M with profit margins of -57.20%. Earnings per share (EPS) is $-0.81.

BEAM

Beam Therapeutics Inc

NASDAQ: BEAM · HEALTHCARE · BIOTECHNOLOGY

$29.38

-3.86% today

Updated 2026-04-29

Market cap

$3.02B

P/E ratio

—

P/S ratio

21.60x

EPS (TTM)

$-0.81

Dividend yield

—

52W range

$15 – $36

Volume

2.1M

Market cap

$3.02B

P/E ratio

—

P/S ratio

21.60x

EPS (TTM)

$-0.81

Dividend yield

—

52W range

$15 – $36

Volume

2.1M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

8.0

Growth

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$51.20

+74.27%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy14 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 279.50% QoQ

Risks

- Thin margins at -57.20%

- Negative free cash flow $-87.02M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$60.92M	$377.71M	$63.52M	$139.74M	$139.74M
Net income	$-289.09M	$-132.53M	$-376.74M	$-79.99M	$244.30M
EPS	—	—	—	—	$-0.81
Free cash flow	$-26.42M	$-182.93M	$-356.19M	$-360.05M	$-87.02M
Profit margin	-474.54%	-35.09%	-593.13%	-57.24%	-57.20%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BEAM	$3.02B	35	8.0	2.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Beam Therapeutics Inc trades at $29.38. Our Smart Value Score of 35/100 indicates the stock is weak. TTM revenue stands at $139.74M. with profit margins at -57.20%.

Frequently asked questions

What is Beam Therapeutics Inc's stock price?

Beam Therapeutics Inc (BEAM) trades at $29.38.

Is Beam Therapeutics Inc overvalued?

Smart Value Score 35/100 (Grade D, Sell).

What is the price target of Beam Therapeutics Inc (BEAM)?

The analyst target price is $51.20, representing +74.3% upside from the current price of $29.38.

What is Beam Therapeutics Inc's revenue?

TTM revenue is $139.74M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio21.60x

ROE-8.11%

Beta2.19

50D MA$27.13

200D MA$24.93

Shares out0.10B

Float0.09B

Short ratio—

Avg volume2.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BEAM vs LLY →BEAM vs JNJ →BEAM vs ABBV →Stock screener →